Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrm syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
A., Braga-Neto, P., and Povoas Barsottini, O
Melanotan II nasal spray specifications In-vitro models and readouts All melanocortin receptors couple to Gs, so cyclic AMP accumulation is the primary functional readout, measured by competitive immunoassay or a live-cell biosensor
complete phase III trials of novel therapies (e.g., targeting mitochondrial function, cellular senescence, microbiome) and facilitate their clinical translation
This may take a minute or two